Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Atlas Oncology Partners

Request full access

Value-based oncology care enablement and risk management platform

Nashville, United StatesFounded 2025Health Tech & Medtech

About Atlas Oncology Partners

Atlas Oncology Partners is a healthcare company that enables value-based oncology care by embedding interdisciplinary teams into community oncology practices and assuming full medical cost risk. The company was founded by the healthcare investment firm Rubicon Founders and officially launched in January 2026 in Memphis, Tennessee, with West Cancer Center & Research Institute as its first partner. The co-founders include President Kate Barnard Roberts, Chief Physician Executive Dr. David Johnson, and Chief of Staff Emma Nosseir.

The firm's business model is centered on partnering with oncologists and payers to improve patient outcomes and experiences while managing the total cost of cancer care. Atlas takes on full financial risk for a patient's medical expenses from payers, such as Medicare Advantage and Commercial plans, through outcomes-based contracts. This aligns financial incentives with the delivery of high-value care. The company then invests in the necessary infrastructure, technology, and clinical staff for its partner practices, insulating them from downside financial risk.

Atlas's service involves embedding a dedicated, local "Extended Care Team" within oncology practices. This team, managed by Atlas, includes providers, nurses, patient navigators, and social workers who deliver comprehensive wrap-around services. Key components of the Atlas care model include proactive care coordination, psychosocial support, 24/7 symptom management triage, management of cancer-adjacent conditions, and advanced supportive care to optimize quality of life. By providing same-day or next-day appointments and other resources, the model aims to reduce avoidable emergency room visits and hospitalizations. The platform unifies multiple data sources to provide actionable insights for providers and supportive care staff. In January 2026, Humana announced a partnership with Atlas to provide these coordinated services to its Medicare Advantage members in Tennessee and Mississippi.

In February 2026, Atlas Oncology Partners announced it had raised $28 million in a Series A funding round. The round was led by Flare Capital Partners with significant participation from Rubicon Founders. The capital is intended to fund geographic expansion with new oncology partners and further investment in clinical and operational infrastructure. The company plans to expand throughout the Southeast in 2026, targeting markets in Alabama, Arkansas, Louisiana, and Texas.

Source: Dealroom company data

At a glance

Status
Operational
Employees
15
Open positions
6
Dealroom signal
84.5/100
Industry
Health
Sub-industry
Health Platform
Sector
Oncology, Chronic Disease
Business model
SaaS
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Feb 2026 $28M $112M Rubicon Founders · Flare Capital Partners ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Atlas Oncology Partners website traffic

Latest recorded traffic for Atlas Oncology Partners is 980 monthly website visits, up 24.1% over the last three months.

Latest monthly visits980 3-month web change+24.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Atlas Oncology Partners in the Nashville ecosystem

Live from Dealroom

The Atlas Oncology Partners office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Flare Capital Partners
  • Rubicon Founders
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Atlas Oncology Partners on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Atlas Oncology Partners’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.